ALVO:NSD-Alvotech (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 8.33

Change

+0.11 (+1.34)%

Market Cap

USD 2.57B

Volume

0.15M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

+4.10 (+1.39%)

USD 13.14B
NBIX Neurocrine Biosciences Inc

+0.07 (+0.06%)

USD 9.54B
VTRS Viatris Inc

-0.06 (-0.69%)

USD 9.00B
LNTH Lantheus Holdings Inc

-0.76 (-0.70%)

USD 7.11B
ALKS Alkermes Plc

-0.38 (-1.20%)

USD 4.74B
HCM HUTCHMED DRC

+0.12 (+0.80%)

USD 2.63B
SUPN Supernus Pharmaceuticals Inc

-0.45 (-1.37%)

USD 1.80B
ANIP ANI Pharmaceuticals Inc

-0.39 (-0.53%)

USD 1.51B
INDV Indivior PLC Ordinary Shares

-0.08 (-0.67%)

USD 1.44B
BCRX BioCryst Pharmaceuticals Inc

+2.10 (+23.52%)

USD 1.43B

ETFs Containing ALVO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.04% 21% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.04% 21% F 19% F
Trailing 12 Months  
Capital Gain -42.07% 41% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.07% 41% F 25% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 12.66% 54% F 70% C-
Dividend Return 12.66% 53% F 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.81% 90% A- 69% C-
Risk Adjusted Return 53.18% 90% A- 80% B-
Market Capitalization 2.57B 91% A- 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.